Orchard Therapeutics announces strategic financing totalling up to $188 million
UCLB spinout, Orchard Therapeutics has announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants that could bring in up to $188 million.
The financing was led by RA Capital Management and attracted new and existing investors Deep Track Capital, Cowen Healthcare Investments, Woodline Partners LP and Zentree Investments Ltd., among others.
Orchard is building on decades of research and advancements in the field of gene therapy to develop potential cures for genetic and other severe diseases.
Read the full story here.